Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 267 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Non Applicable Clear all
Completed Phase 3 Interventional Results available

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

NCT00410202
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Tenofovir, Adefovir, Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 9, 2026, 1:45 AM EDT
Not yet recruiting Not applicable Interventional

Emergency Department-Initiated Team-Based Care for Severe Hypertension

NCT07777237
View directory record Official record
Conditions
Severe Hypertension, Hypertension
Interventions
Emergency Department-Initiated Team-Based Care, Usual Care
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Dearborn, Michigan • Detroit, Michigan • Wyandotte, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 9, 2026, 1:45 AM EDT
Completed No phase listed Observational Results available

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

NCT05214573
View directory record Official record
Conditions
Type 2 Diabetes, Cardiac Disease
Interventions
Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
386,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

NCT03591354
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM
Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 9, 2026, 1:45 AM EDT
Completed No phase listed Observational

A Retrospective, Observational Study of the Real-world Safety and Performance of InnovaMatrix® AC at a Single Centre

NCT07170566
View directory record Official record
Conditions
Wound Heal
Interventions
innovaMatrix AC
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
Not yet recruiting Phase 2 Interventional

Off-Label Treatment With Immune Checkpoint Inhibitor Blockade

NCT07754292
View directory record Official record
Conditions
Malignancy
Interventions
One or more off-label ICIs alone or with other on-label ICI(s), Off-label ICI(s) with targeted therapy, off-label ICI(s) with other agents that are not targeted (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy other than ICIs) with or without targeted agents
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 9, 2026, 1:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
EO2463, lenalidomide, rituximab
Biological · Drug
Lead sponsor
Enterome
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

NCT04398706
View directory record Official record
Conditions
Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions
Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 15 Months
Enrollment
852 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
49
States / cities
Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption

NCT02520258
View directory record Official record
Conditions
Glucose Metabolism Disorder
Interventions
Oral glucose tolerance test (OGTT), Diet soda containing aspartame only
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 9, 2026, 1:45 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Neural and Cognitive Consequences of COVID-19 Survival

NCT06208943
View directory record Official record
Conditions
COVID Long-Haul, COVID-19, COVID-19 Pandemic, Brain Fog, Memory Deficits, Concentration Ability Impaired, Fatigue
Interventions
cross-sectional MRI and EEG assessments (NO INTERVENTION)
Other
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults

NCT04284553
View directory record Official record
Conditions
Aging, Benzodiazepine Sedative Adverse Reaction, Anticholinergic Adverse Reaction, Adverse Drug Event
Interventions
Order Entry, Open Encounter, Follow-up booster Alert, Cold State outreach, Simplified, Sign-off alert, Pre-commitment, Different Risks, Standard Epic Basic Alert, Enhanced Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Braintree, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Hybrid Type 2 Trial of Trauma-Focused Cognitive Behavioral Therapy and a Pragmatic Individual-Level Implementation Strategy

NCT04451161
View directory record Official record
Conditions
Evidence-Based Practices, CBT, School Health Services, Trauma, Psychological
Interventions
Beliefs and Attitudes for Successful Implementation in Schools (BASIS), Trauma-Focused Cognitive-Behavioral Therapy, Treatment as Usual, Attention Control
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
7 Years to 85 Years
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

Together Overcoming Diabetes

NCT04734015
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Together Overcoming Diabetes (TOD)
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
10 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 9, 2026, 1:45 AM EDT
Recruiting No phase listed Observational

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

NCT06170268
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Routine Care Documentation
Other
Lead sponsor
Alzheimer's Disease and Related Disorders Association, Inc
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT04150913
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
Interventions
Anakinra, Axicabtagene Ciloleucel
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

NCT02560584
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate hydrochloride, KARL STORZ D-Light C PDD Flexible Videoscope System
Drug · Device
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Los Angeles, California • Chicago, Illinois • Iowa City, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional

Upper Extremity Life Care Specialist (LCS)

NCT05422014
View directory record Official record
Conditions
Upper Extremity Trauma
Interventions
Life Care Specialist (LCS)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 1:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Outcome Assessment for AT & BCI

NCT07407725
View directory record Official record
Conditions
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Eye Tracker, Mouth Operated Joystick, Non-invasive electroencephalogram (EEG) Headset, Implantable Brain-Computer-Interface, Personal Assistive Technology, Voice Control
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Ultraprocessed Food Labels in Chile

NCT06842680
View directory record Official record
Conditions
Diet, Healthy
Interventions
Control, Ultraprocessed warning label
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
3,645 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL

NCT02187354
View directory record Official record
Conditions
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 17 Years
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Not applicable Interventional Results available

Co-Use of Opioid Medications and Alcohol Prevention Study

NCT05599672
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use
Interventions
Alcohol-targeted Brief Intervention-Medication Therapy Management, Standard medication counseling
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 9, 2026, 1:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

NCT03369002
View directory record Official record
Conditions
Hepatic Impairment
Interventions
seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 9, 2026, 1:45 AM EDT